CFO on leave

[Anonymous]

Uroplasty places CFO on leave, delays filing annual report
7:25 AM ET, 06/14/2013 - Reuters

June 14 (Reuters) - Medical device maker Uroplasty Inc said it placed Chief Financial Officer Mahedi Jiwani on administrative leave pending a review of internal financial controls, and would delay filing its annual report for the year ended March 31.

Shares of the company were down about 20 percent at $1.98 in thin trading before the bell.

The company said an initial review of employee expense reimbursements at the end of the fiscal year showed "limited issues" related to internal controls.

Uroplasty, which sells devices to treat loss of bladder control, later discovered issues related to the recognition of orders and payment of sales commissions - warranting a further review.

"The review is being conducted at the direction of the audit committee of the board of directors of the company, with the assistance of independent advisors," Uroplasty said in a statement.

The Minnetonka, Minnesota-based company said it is unable to fully assess the potential impact on its financial statements as the review of internal control issues has not been completed.

Mahedi Jiwani has been Uroplasty's chief financial officer since November 2005, according to Thomson Reuters data. (Reporting by Pallavi Ail in Bangalore; Editing by Roshni Menon)

 

[Anonymous]

Citing financial issues, Uroplasty puts CFO on leave, delays filing with SEC
Article by: STEVE ALEXANDER , Star Tribune
Updated: June 14, 2013 - 8:35 PM

Company is reviewing order recognition process and sales commissions, but says earnings figures unlikely to be affected.

At medical tech firm Uroplasty Inc., things are going from bad to worse.

The Minnetonka firm’s CEO resigned in April. And Friday the company placed Chief Financial Officer Mahedi Jiwani on administrative leave and delayed filing its 10-K annual report to the Securities and Exchange Commission pending “a review of its internal control over financial reporting.”

The news caused Uroplasty’s stock to drop sharply. It closed at $2.22 a share, down 26 cents, or 10.5 percent.

Friday’s bad news followed last month’s financial disappointment, when the Minnetonka manufacturer of urinary dysfunction products reported a fiscal 2012 loss of $3.3 million, or 16 cents a share, on revenue of $22.4 million.



Ads by Google

Business Loans $100K-$2MMGet A Small Business Loan In 5 Days A+ Rated By BBB. No Startups, Apply BusinessFinancialServices.com/Loan


During a conference call with analysts last month, interim CEO Robert Kill said the fourth-quarter results “were disappointing and reflect poor execution on our part.” Kill replaced CEO David Kaysen, who resigned.

The company said in a statement Friday that its decision to put its CFO on administrative leave followed the discovery of financial issues during a review of employee expense reimbursements after the end of its fiscal year in March.

Initially Uroplasty officials believed the issues weren’t likely to have a material impact on its financial statements. But then the company discovered there were issues with “the recognition of orders and the payment of sales commissions at the end of fiscal quarters,” the firm said in a statement.

Bad timing

“Based upon facts available, the company does not currently believe that a material revision of its previously released earnings is likely,” the statement said. “However, the review of internal control issues has not been completed and the company is unable at this time to fully assess the potential impact on its financial statements.”

Uroplasty’s troubles come at a bad time, said Jack Militello, a management professor and director of the health care MBA program at the University of St. Thomas. That’s because even the appearance of ethical lapses damages a company’s reputation with investors, making it harder for a firm such as Uroplasty to deal with the medical device pricing pressures that lie just ahead, he said.

Those pressures are building because small medical device companies face increasing competition from start-ups; the costs of complying with Food and Drug Administration rules, and an impending tax on medical devices to help pay for the Affordable Care Act, Militello said. The tax, whose magnitude hasn’t been determined yet, could be particularly hurtful to small medical device companies, he said.

“Can the Uroplasty ship be righted? Here are the things weighing against it: They don’t have a lot of time given that the health care law changes are coming, that repairing a business culture is more difficult than just changing a CEO, and that the stock is down because investors don’t trust the company’s financial numbers,” he said.

But there are also reasons to believe management can succeed, Militello said.

“Let’s assume that mistakes were made, but that the board has done the right thing,” Militello said. “That would put a vote of confidence on the side of the organization and would steady investors. The interim CEO then has time to work on the company’s culture, prestige and message. Then the answer about whether he’s been successful comes six months from now.”

Steve Alexander • 612-673-4553

 

[Anonymous]

Citing financial issues, Uroplasty puts CFO on leave, delays filing with SEC
Article by: STEVE ALEXANDER , Star Tribune
Updated: June 14, 2013 - 8:35 PM

Company is reviewing order recognition process and sales commissions, but says earnings figures unlikely to be affected.

At medical tech firm Uroplasty Inc., things are going from bad to worse.

The Minnetonka firm’s CEO resigned in April. And Friday the company placed Chief Financial Officer Mahedi Jiwani on administrative leave and delayed filing its 10-K annual report to the Securities and Exchange Commission pending “a review of its internal control over financial reporting.”

The news caused Uroplasty’s stock to drop sharply. It closed at $2.22 a share, down 26 cents, or 10.5 percent.

Friday’s bad news followed last month’s financial disappointment, when the Minnetonka manufacturer of urinary dysfunction products reported a fiscal 2012 loss of $3.3 million, or 16 cents a share, on revenue of $22.4 million.



Ads by Google

Business Loans $100K-$2MMGet A Small Business Loan In 5 Days A+ Rated By BBB. No Startups, Apply BusinessFinancialServices.com/Loan


During a conference call with analysts last month, interim CEO Robert Kill said the fourth-quarter results “were disappointing and reflect poor execution on our part.” Kill replaced CEO David Kaysen, who resigned.

The company said in a statement Friday that its decision to put its CFO on administrative leave followed the discovery of financial issues during a review of employee expense reimbursements after the end of its fiscal year in March.

Initially Uroplasty officials believed the issues weren’t likely to have a material impact on its financial statements. But then the company discovered there were issues with “the recognition of orders and the payment of sales commissions at the end of fiscal quarters,” the firm said in a statement.

Bad timing

“Based upon facts available, the company does not currently believe that a material revision of its previously released earnings is likely,” the statement said. “However, the review of internal control issues has not been completed and the company is unable at this time to fully assess the potential impact on its financial statements.”

Uroplasty’s troubles come at a bad time, said Jack Militello, a management professor and director of the health care MBA program at the University of St. Thomas. That’s because even the appearance of ethical lapses damages a company’s reputation with investors, making it harder for a firm such as Uroplasty to deal with the medical device pricing pressures that lie just ahead, he said.

Those pressures are building because small medical device companies face increasing competition from start-ups; the costs of complying with Food and Drug Administration rules, and an impending tax on medical devices to help pay for the Affordable Care Act, Militello said. The tax, whose magnitude hasn’t been determined yet, could be particularly hurtful to small medical device companies, he said.

“Can the Uroplasty ship be righted? Here are the things weighing against it: They don’t have a lot of time given that the health care law changes are coming, that repairing a business culture is more difficult than just changing a CEO, and that the stock is down because investors don’t trust the company’s financial numbers,” he said.

But there are also reasons to believe management can succeed, Militello said.

“Let’s assume that mistakes were made, but that the board has done the right thing,” Militello said. “That would put a vote of confidence on the side of the organization and would steady investors. The interim CEO then has time to work on the company’s culture, prestige and message. Then the answer about whether he’s been successful comes six months from now.”

Steve Alexander • 612-673-4553

With 10 sales reps openings, there is NO WAY the company can come close to hitting their numbers.

 

[Anonymous]

With 10 sales reps openings, there is NO WAY the company can come close to hitting their numbers.

With data that shows no difference in efficacy between older OAB drugs and PTNS, there is NO WAY the company can come close to hitting their numbers.

OrBiT data is weak.

SuMiT data is weak.

PTNS is weak